EC
CNTA

EntryPoint Capital’s Centessa Pharmaceuticals CNTA Stock Holding History

EntryPoint Capital’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-13,651
Closed -$218K – 761
2024
Q3 		$218K Buy
13,651
+5,515
+68% +$67.6K 0.12% 412
2024
Q2 		$73.5K Sell
8,136
-1,500
-16% -$14.2K 0.11% 433
2024
Q1 		$109K Buy
+9,636
New +$91.2K 0.1% 373

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
IVLAV
Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EntryPoint Capital's CNTA Position: Q4 2024 in Review

EntryPoint Capital sold out of Centessa Pharmaceuticals (CNTA) in Q4 2024, closing a stake of 13,651 shares — an estimated $218K sold.

EntryPoint Capital first reported a position in CNTA in Q1 2024 and held it in 3 quarters. The position peaked at $218K in Q3 2024. 114 funds tracked by Wall St. Rank hold CNTA as of Q4 2024.

  • EntryPoint Capital reported no remaining Centessa Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • EntryPoint Capital sold 13,651 Centessa Pharmaceuticals shares in Q4 2024, an estimated $218K.
  • EntryPoint Capital first reported a position in Centessa Pharmaceuticals in Q1 2024 and held it in 3 quarters.
  • EntryPoint Capital's Centessa Pharmaceuticals position peaked at $218K in Q3 2024.
  • 114 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q4 2024.

Based on EntryPoint Capital's 13F filing for Q4 2024, filed 11 Feb 2025.